Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073385 · ClinicalTrials.gov registry record · Phase 2
Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Titan Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
NCT00073385 is a Phase 2 study that has completed, run by Titan Pharmaceuticals. The registered enrollment target is 225 participants.
The verdict
NCT00073385, a Phase 2 study, has completed, sponsored by Titan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
Study Summary
This randomized study will assess the efficacy and safety of the combination of Pivanex and docetaxel compared to docetaxel alone in patients with a type of lung cancer called non-small cell lung cancer. Pivanex is an investigational agent, and docetaxel is an approved drug.
Interventions
- DRUG Docetaxel
- DRUG Pivanex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2003-09 |
| Est. Completion | 2004-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073385
The ClinicalTrials.gov registry entry for NCT00073385 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Titan Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00073385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073385 about?
NCT00073385 is a clinical study titled "Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer". This randomized study will assess the efficacy and safety of the combination of Pivanex and docetaxel compared to docetaxel alone in patients with a type of lung cancer called non-small cell lung cancer. Pivanex is an investigational agent, and docetaxel is an approved drug.
What is the current status of trial NCT00073385?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2003-09. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00073385?
The interventions under investigation include: Docetaxel (DRUG), Pivanex (DRUG).
Who is sponsoring clinical trial NCT00073385?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.